ARA-290 10mg

ARA-290, also called cibinetide, is a synthetic 11-amino-acid peptide derived from helix B of human erythropoietin (EPO). It was designed by Anthony Cerami and colleagues to capture EPO's tissue-protective signaling — which acts through the innate repair receptor (IRR) — while shedding the erythropoietic activity that comes from EPO's binding to homodimeric EPO receptors on red-cell precursors. The molecule reached clinical investigation as a candidate for neuropathic pain, diabetic neuropathy, and sarcoidosis-related conditions. This guide explains what ARA-290 is, the published research context, and how its quality is independently verified.

ARA-290 has the sequence pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser — 11 residues with a pyroglutamate (pyroGlu, also written pE) at the N-terminus. The pyroglutamate is a cyclized derivative of glutamate that forms via intramolecular condensation; it is the natural N-terminal modification of many endogenous peptides and is reproduced synthetically in ARA-290 because it improves resistance to N-terminal aminopeptidases. The molecular weight is approximately 1257 g/mol. It is supplied as a lyophilized white powder for laboratory reconstitution.

ARA-290 is sold strictly for laboratory and research use. It is not approved by the FDA or any other regulatory body for human or veterinary use, and nothing in this guide constitutes guidance for human administration.

Published research on ARA-290 centers on the innate repair receptor (IRR) — a heteromeric receptor combining the EPO receptor (EPOR) and the common β receptor (CD131, also called βcR). The IRR is expressed on a variety of cells outside the red-cell lineage, including neurons, vascular endothelium, and immune cells. ARA-290 binds this heteromeric receptor with relatively high affinity but does not productively engage the homodimeric EPOR found on red-cell precursors, which is why it produces tissue-protective signaling without driving erythropoiesis. Reported research effects include neuroprotection in diabetic peripheral neuropathy models, anti-inflammatory effects in immune-cell systems, and analgesic effects in neuropathic-pain models. Researchers should evaluate the Cerami group's publications and the clinical literature on cibinetide directly.

Every batch of MHS Longevity ARA-290 is submitted to an independent third-party laboratory before release. The N-terminal pyroglutamate is a specific verification target alongside standard purity testing:

Lyophilized ARA-290 should be stored at -20°C or below for extended stability. Once reconstituted in bacteriostatic water, the solution is typically held at 2–8°C and used within the documented stability window. The pyroglutamate N-terminus is generally stable but can slowly hydrolyze back to glutamate under prolonged aqueous conditions, particularly at elevated temperature — single-use aliquoting after reconstitution helps preserve the cyclized form across a study timeline. Standard aseptic technique applies.